GUERBET Overview
Industry: Medical Devices
Sector: Healthcare
Research snapshot
Latest filing date 2026-03-24This Mavefund research page organizes verified information for GUERBET (GBT.PA), including the company profile, price history, source-linked filings, available financial statements, research signals, and risks to review.
- Listing
- GBT.PA · PAR · MIC XPAR
- Country
- FR
- Trading currency
- EUR
- Industry
- Medical Devices
- Financial coverage
- Annual statements available
- Latest filing source
- XBRL International ESEF · filed 2026-03-24
Primary sources
- Latest XBRL International ESEF filing Filed 2026-03-24
- Verified listing source
Coverage is refreshed automatically and published only after data-integrity validation. Research support only; not personalized financial advice.
Reported Results
What the company reported, with filing details kept small.
Annual result summary
Latest company-filed earnings material is available for source review.
What changed
- Review the source filing for the full reported results and management commentary.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.
ESEF annual report
Open filing
Sources: XBRL International ESEF. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
No qualified company news in the last 14 days
No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.
Financial Statements
Company-reported filing facts, organized and linked to the original source.
Verified source-linked statements load when this section enters view.
Source details load with the filing data. Values are standardized company disclosures for research support, not personalized financial advice.